Differential Effects of PD-1 and PD-L1 Immune Checkpoint Inhibition on Cognition and Anxiety-Like Behavior Through ΓδT Cells and Tumor–Dependent Neuroinflammation

Why It Matters

The findings reveal a mechanistic link between PD‑L1 blockade, γδ T‑cell activity, and cancer‑related cognitive impairment, highlighting a potential target to protect patients undergoing immunotherapy.

Key Takeaways

• Immuno‑excluded and immuno‑inflamed tumors impair short‑term memory.
• Anti‑PD‑L1 increases BBB permeability and circulating γδ T cells.
• γδ T‑cell neutralization restores cognition without reducing anti‑PD‑L1 efficacy.
• Tumor immunoscore correlates with anxiety‑like behavior in mice.
• IL‑6/IL‑17 surge links immuno‑inflamed MC38 tumors to neuroinflammation.

Pulse Analysis

Cancer‑related cognitive impairment (CRCI) has emerged as a serious side effect of modern immunotherapies, yet its biological roots remain murky. Recent work categorizes tumors by immune landscape—desert, excluded, and inflamed—and shows that excluded and inflamed models already disrupt short‑term memory and elevate anxiety‑like responses in mice. These behavioral changes parallel systemic cytokine spikes, meningeal transcriptional shifts, and, in the inflamed MC38 model, a pronounced IL‑6/IL‑17 surge that compromises the blood‑brain barrier and hippocampal neurogenesis.

The study contrasts two checkpoint inhibitors: anti‑PD‑1 and anti‑PD‑L1. While both agents leave behavior unchanged in tumor‑free mice, anti‑PD‑L1 uniquely aggravates CRCI in tumor‑bearing subjects. It drives BBB leakage, recruits γδ T cells to vascular interfaces, and amplifies CD3⁺ T‑cell infiltration and vascular inflammation in the brain. Notably, experimental neutralization of γδ T cells rescues memory and anxiety metrics without dampening the anti‑tumor efficacy of PD‑L1 blockade, pinpointing these cells as a pivotal mediator of neurotoxicity.

Clinically, the research suggests that monitoring γδ T‑cell levels and BBB integrity could flag patients at risk for immunotherapy‑induced neurocognitive decline. Moreover, therapeutic strategies that selectively inhibit γδ T‑cell activity may preserve cognitive function while maintaining cancer control. As checkpoint inhibitors become first‑line for many solid tumors, integrating neuroprotective biomarkers into treatment protocols could improve quality of life and long‑term outcomes for survivors.